News
-
-
-
COMMUNIQUÉ DE PRESSE
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics reports positive results from Phase 2 study of Lusvertikimab for Ulcerative Colitis treatment. Primary endpoint met with high clinical and endoscopic remission rates -
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Brockhaus Technologies AG: High profitability and organic growth in 9M 2024; revenue increases by +22.9% to €175m and adj. EBITDA by +25.0% to €68m (38.8% margin) – 2024 forecast confirmed
Brockhaus Technologies AG reports high profitability and organic growth in 9M 2024, with revenue up by +22.9% to €175m and adj. EBITDA by +25.0% to €68m. Forecast for 2024 confirmed -
-
